SEC FORM 3 SEC Form 3
FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response: 0.5
1. Name and Address of Reporting Person*
Temperato John

(Last) (First) (Middle)
C/O MELINTA THERAPEUTICS, INC.
300 GEORGE STREET, SUITE 301

(Street)
NEW HAVEN CT 06511

(City) (State) (Zip)
2. Date of Event Requiring Statement (Month/Day/Year)
11/03/2017
3. Issuer Name and Ticker or Trading Symbol
MELINTA THERAPEUTICS, INC. /NEW/ [ MLNT ]
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Commercial Officer
5. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy) (1) 03/21/2026 Common Stock 72,135 38 D
Stock Option (Right to Buy) (2) 08/07/2027 Common Stock 6,615 20.97 D
Explanation of Responses:
1. The option vests 1/4 on February 16, 2017 and 1/48 every month thereafter.
2. The option vests 1/4 on August 8, 2018 and 1/48 every month thereafter.
Remarks:
/s/ Alexander M. Donaldson, by Power of Attorney 11/13/2017
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
POWER OF ATTORNEY

	Know all by these presents, that the undersigned hereby constitutes and
appoints each of Kenneth E. Eheman, Alexander M. Donaldson and S. Halle Vakani,
and each of them acting alone, signing singly, the undersigned's true and lawful
attorney-in-fact to:  (1) execute for and on behalf of the undersigned, in the
undersigned's capacity as an officer, director and/or 10% or more stockholder of
Melinta Therapeutics, Inc. (the "Company"), Forms 3, 4 and 5, and Update
Passphrase Acknowledgement  (and any amendments thereto) in accordance with
Section 16(a) of the Securities Exchange Act of 1934, as amended (the "1934
Act"), and the rules promulgated thereunder; (2) do and perform any and all acts
for and on behalf of the undersigned which may be necessary or desirable to
complete and execute any such Form 3, 4 and 5, and Update Passphrase
Acknowledgement (and any amendments thereto) and to file timely such form with
the United States Securities and Exchange Commission and any stock exchange or
similar authority; and (3) take any other action of any type whatsoever in
connection with the foregoing which in the opinion of such attorney-in-fact, may
be of benefit to, in the best interest of, or legally required by, the
undersigned, it
 being understood that the documents executed by such
attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney
shall be in such form and shall contain such terms and conditions as such
attorney-in-fact may approve in such attorney-in-fact's discretion.

	The undersigned hereby grants to each such attorney-in-fact full power and
authority to do and perform any and every act and thing whatsoever requisite,
necessary or proper to be done in the exercise of any of the rights and powers
herein granted, as fully to all intents and purposes as the undersigned might or
could do if personally present, with full power of substitution or revocation,
hereby ratifying and confirming all that such attorney-in-fact, or such
attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be
done by virtue of this power of attorney and the rights and powers herein
granted.  The undersigned acknowledges that the foregoing attorneys-in-fact, in
serving in such capacity at the request of the undersigned, are not assuming,
nor is the Company assuming, any of the undersigned's responsibilities to comply
with Section 16 of the 1934 Act.

	This Power of Attorney shall remain in full force and effect until the
undersigned is no longer required to file Forms 3, 4 and 5, and Update
Passphrase Acknowledgement with respect to the undersigned's holdings of and
transactions in securities issued by the Company, unless earlier revoked by the
undersigned, in a signed writing delivered to each of the foregoing
attorneys-in-fact.

	IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be
executed as of this 9th day of November 2017.



/s/ John Temperato											
John Temperato